Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01686815 · ClinicalTrials.gov registry record
Cross-Sectional Iloperidone IVGTT
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 37
- Enrollment target
NCT01686815: Completed study, sponsored by Massachusetts General Hospital.
NCT01686815 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01686815 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
This study aims to utilize state of the art procedures such as the frequently sampled intravenous glucose tolerance test (FSIVGTT), Bergman's Minimal Model Analysis, lipoprotein analysis, and DEXA scans to demonstrate that a newer agent, iloperidone, is devoid of the metabolic abnormalities associated with other atypical antipsychotic treatments, namely olanzapine and risperidone, and offers an advantage over these other agents.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01686815
The ClinicalTrials.gov registry entry for NCT01686815 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01686815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01686815 about?
NCT01686815 is a clinical study titled "Cross-Sectional Iloperidone IVGTT". This study aims to utilize state of the art procedures such as the frequently sampled intravenous glucose tolerance test (FSIVGTT), Bergman's Minimal Model Analysis, lipoprotein analysis, and DEXA scans to demonstrate that a newer agent, iloperidone, is devoid of the metabolic abnormalities associat...
What is the current status of trial NCT01686815?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2012-10. Estimated completion is 2016-05.
Who is sponsoring clinical trial NCT01686815?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.